NASDAQ:CTIC - CTI BioPharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.83 +0.07 (+1.47 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$4.76
Today's Range$4.65 - $4.83
52-Week Range$2.45 - $4.99
Volume201,300 shs
Average Volume349,478 shs
Market Capitalization$277.71 million
P/E Ratio-3.90
Dividend YieldN/A
Beta0.14

About CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma logoCTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. The company's product candidate in pipeline includes tosedostat, a novel oral, once-daily aminopeptidase inhibitor for patients with acute myeloid leukemia. It has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; Teva Pharmaceutical Industries Ltd; University of Vermont; S*BIO Pte Ltd; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTIC
CUSIPN/A
Phone206-282-7100

Debt

Debt-to-Equity Ratio0.17
Current Ratio5.32
Quick Ratio5.30

Price-To-Earnings

Trailing P/E Ratio-3.90
Forward P/E Ratio-5.08
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.15 million
Price / Sales11.13
Cash FlowN/A
Price / CashN/A
Book Value$1.33 per share
Price / Book3.63

Profitability

EPS (Most Recent Fiscal Year)($1.24)
Net Income$-40,670,000.00
Net Margins-71.30%
Return on Equity-63.27%
Return on Assets-30.84%

Miscellaneous

Employees57
Outstanding Shares57,980,000

CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

Shares of CTI BioPharma reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma (NASDAQ:CTIC) announced its quarterly earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02. The biopharmaceutical company earned $10.48 million during the quarter, compared to analysts' expectations of $10.30 million. CTI BioPharma had a negative return on equity of 63.27% and a negative net margin of 71.30%. View CTI BioPharma's Earnings History.

When is CTI BioPharma's next earnings date?

CTI BioPharma is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for CTI BioPharma.

What price target have analysts set for CTIC?

5 brokerages have issued twelve-month price targets for CTI BioPharma's shares. Their forecasts range from $5.00 to $10.00. On average, they expect CTI BioPharma's share price to reach $7.10 in the next twelve months. View Analyst Ratings for CTI BioPharma.

What are Wall Street analysts saying about CTI BioPharma stock?

Here are some recent quotes from research analysts about CTI BioPharma stock:
  • 1. According to Zacks Investment Research, "CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its late-stage development pipeline, including pacritinib. CTI BioPharma Corp., formerly known as Cell Therapeutics, Inc., is headquartered in Seattle, Washington. " (4/25/2018)
  • 2. Cann analysts commented, "CTI BioPharma released Q4 2017 results today with lower-than-expected sales and slightly higher-than-estimated SG&A. Total revenue of $462,000 was lower than our estimated $1.7 million. All revenue was from License and Contract Revenue. Total operating expenses of $14.2 million were 6.3% higher than our estimated $13.3 million due to higher-than-estimated SG&A expense. CTI BioPharma lost $0.33 per share compared to our estimated loss per share of $0.28. Our 2018–2024 outlook is basically unchanged for CTI BioPharma. Programs are advancing, with data expected in H1 2018." (3/7/2018)

Who are some of CTI BioPharma's key competitors?

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the folowing people:
  • Dr. Jack W. Singer, Co-Founder, Exec. VP, Chief Scientific Officer, Interim CMO & Global Head-Translational Medicine (Age 75)
  • Mr. Bruce J. Seeley, COO, Exec. VP & Sec. (Age 54)
  • Dr. Adam R. Craig, Pres, CEO & Director (Age 52)
  • Mr. David H. Kirske, Exec. VP & CFO (Age 64)
  • Mr. Ed Bell, Sr. Director of Investor Relations

Has CTI BioPharma been receiving favorable news coverage?

News stories about CTIC stock have been trending somewhat positive on Friday, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CTI BioPharma earned a daily sentiment score of 0.15 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.47 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BVF Inc. IL (11.95%), NEA Management Company LLC (6.47%), Franklin Resources Inc. (5.99%), Millennium Management LLC (1.36%), BlackRock Inc. (0.75%) and JPMorgan Chase & Co. (0.46%). Company insiders that own CTI BioPharma stock include Bvf Partners L P/Il, James A Bianco, Richard L Love and Value Fund L P Biotechnology. View Institutional Ownership Trends for CTI BioPharma.

Which major investors are selling CTI BioPharma stock?

CTIC stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL and United Capital Financial Advisers LLC. View Insider Buying and Selling for CTI BioPharma.

Which major investors are buying CTI BioPharma stock?

CTIC stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Franklin Resources Inc., Millennium Management LLC, JPMorgan Chase & Co., Tibra Equities Europe Ltd, Northern Trust Corp, Element Capital Management LLC and Barclays PLC. Company insiders that have bought CTI BioPharma stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for CTI BioPharma.

How do I buy shares of CTI BioPharma?

Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $4.83.

How big of a company is CTI BioPharma?

CTI BioPharma has a market capitalization of $277.71 million and generates $25.15 million in revenue each year. The biopharmaceutical company earns $-40,670,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. CTI BioPharma employs 57 workers across the globe.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]


MarketBeat Community Rating for CTI BioPharma (CTIC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  177 (Vote Underperform)
Total Votes:  333
MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma and other stocks. Vote "Outperform" if you believe CTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CTI BioPharma (NASDAQ:CTIC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for CTI BioPharma in the last 12 months. Their average twelve-month price target is $7.10, suggesting that the stock has a possible upside of 47.00%. The high price target for CTIC is $10.00 and the low price target for CTIC is $5.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.10$7.10$6.25$7.50
Price Target Upside: 47.00% upside83.94% upside68.46% upside131.48% upside

CTI BioPharma (NASDAQ:CTIC) Consensus Price Target History

Price Target History for CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma (NASDAQ:CTIC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/26/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$10.00HighView Rating Details
3/7/2018CannReiterated RatingBuy$5.00LowView Rating Details
3/7/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$8.00LowView Rating Details
2/23/2018OppenheimerInitiated CoverageOutperform$5.00 ➝ $5.00HighView Rating Details
9/12/2017Jefferies GroupInitiated CoverageBuy ➝ Buy$7.50HighView Rating Details
8/29/2016Piper Jaffray CompaniesReiterated RatingNeutral$7.50N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

CTI BioPharma (NASDAQ:CTIC) Earnings History and Estimates Chart

Earnings by Quarter for CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma (NASDAQ:CTIC) Earnings Estimates

2018 EPS Consensus Estimate: ($1.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.07)($0.07)($0.07)
Q2 20181($0.27)($0.27)($0.27)
Q3 20181($0.31)($0.31)($0.31)
Q4 20181($0.44)($0.44)($0.44)

CTI BioPharma (NASDAQ CTIC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2018        
5/3/2018Q1 2018($0.10)($0.08)$10.30 million$10.48 millionViewN/AView Earnings Details
3/7/2018Q4 2017($0.29)($0.33)$1.00 million$0.46 millionViewListenView Earnings Details
11/6/2017Q3 2017($0.32)($0.28)$0.30 million$1.71 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.60)$0.03$22.23 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.70)($0.71)$0.75 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.70)($0.23)$9.14 millionViewListenView Earnings Details
11/8/2016Q3 2016($0.70)($1.00)$4.43 millionViewN/AView Earnings Details
8/4/2016Q2($0.10)($0.07)$7.36 millionViewN/AView Earnings Details
5/10/2016Q1($0.04)$0.01$36.48 millionViewN/AView Earnings Details
2/16/2016Q4($0.18)($0.13)$11.32 millionViewN/AView Earnings Details
11/5/2015Q315($0.12)($0.19)$18.89 million$1.00 millionViewListenView Earnings Details
8/6/2015Q215($0.10)($0.19)$12.77 million$1.10 millionViewListenView Earnings Details
5/6/2015Q115($0.14)($0.16)$9.84 million$2.73 millionViewListenView Earnings Details
3/12/2015Q414($0.18)($0.27)$2.48 million$17.80 millionViewListenView Earnings Details
10/29/2014Q3$0.03$0.03$21.52 million$39.53 millionViewListenView Earnings Details
8/4/2014Q2($0.12)($0.19)$11.79 million$1.34 millionViewListenView Earnings Details
4/29/2014Q114($0.20)($0.20)$1.10 million$1.40 millionViewN/AView Earnings Details
3/4/2014Q4($0.16)$0.08$1.26 million$32.90 millionViewListenView Earnings Details
10/30/2013Q3 2013($1.70)($2.00)$2.00 million$0.36 millionViewN/AView Earnings Details
7/31/2013Q2 2013($1.70)($1.70)$1.50 million$0.31 millionViewN/AView Earnings Details
5/2/2013Q1 2013($4.40)($1.80)$1.13 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.20)($0.20)$1.00 millionViewListenView Earnings Details
11/1/2012Q312($0.38)ViewN/AView Earnings Details
8/1/2012Q2 2012($7.15)ViewN/AView Earnings Details
4/20/2012Q1 2012($5.00)($4.30)ViewN/AView Earnings Details
3/7/2012Q4 2011($4.00)($7.40)ViewN/AView Earnings Details
10/25/2011Q3 2011($5.50)($8.00)ViewN/AView Earnings Details
7/28/2011Q2 2011($6.00)($6.80)ViewN/AView Earnings Details
4/27/2011Q1 2011($6.00)($17.40)ViewN/AView Earnings Details
2/16/2011Q4 2010($6.00)($12.00)ViewN/AView Earnings Details
10/28/2010Q3 2010($18.00)($6.60)ViewN/AView Earnings Details
8/5/2010Q2 2010($6.00)($23.10)ViewN/AView Earnings Details
4/28/2010Q1 2010($22.20)ViewN/AView Earnings Details
2/11/2010Q4 2009($9.00)($14.40)ViewN/AView Earnings Details
11/5/2009Q3 2009($27.89)ViewN/AView Earnings Details
8/6/2009Q2 2009($15.00)($15.30)ViewN/AView Earnings Details
5/7/2009Q1 2009($80.98)($26.99)ViewN/AView Earnings Details
3/16/2009Q4 2008($287.94)($162.57)ViewN/AView Earnings Details
11/7/2008Q3 2008($1,019.80)($850.03)ViewN/AView Earnings Details
8/18/2008Q2 2008($1,049.79)($1,406.72)ViewN/AView Earnings Details
5/8/2008Q1 2008($1,409.72)($2,303.54)ViewN/AView Earnings Details
3/13/2008Q4 2007($1,649.67)($2,231.55)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

CTI BioPharma (NASDAQ:CTIC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

CTI BioPharma (NASDAQ CTIC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.72%
Institutional Ownership Percentage: 62.67%
Insider Trading History for CTI BioPharma (NASDAQ:CTIC)
Institutional Ownership by Quarter for CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma (NASDAQ CTIC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2018Bvf Partners L P/IlMajor ShareholderBuy5,634,108$3.00$16,902,324.00View SEC Filing  
2/9/2018Value Fund L P BiotechnologyInsiderBuy6,333,333$3.00$18,999,999.00View SEC Filing  
9/29/2017Richard L LoveDirectorSell14,600$3.21$46,866.0084,318View SEC Filing  
6/24/2016James A BiancoCEOSell10,000$0.37$3,700.001,780,133View SEC Filing  
5/27/2016James A BiancoCEOSell10,000$0.45$4,500.001,790,133View SEC Filing  
4/29/2016James A BiancoCEOSell10,000$0.52$5,200.001,800,133View SEC Filing  
3/28/2016James A BiancoCEOSell10,000$0.49$4,900.001,810,133View SEC Filing  
3/21/2016James A BiancoCEOSell318,169$0.55$174,992.951,820,133View SEC Filing  
3/4/2016Matthew PlunkettEVPSell10,000$0.59$5,900.00598,784View SEC Filing  
2/26/2016Jack W SingerEVPSell15,000$0.63$9,450.001,054,892View SEC Filing  
2/26/2016James A BiancoCEOSell10,000$0.63$6,300.002,138,302View SEC Filing  
2/16/2016James A BiancoCEOSell100,000$0.42$42,000.002,148,302View SEC Filing  
2/4/2016Matthew PlunkettEVPSell10,000$1.15$11,500.00600,084View SEC Filing  
1/29/2016Jack W. SingerEVPSell15,000$1.18$17,700.001,054,992View SEC Filing  
1/29/2016James A BiancoCEOSell10,000$1.20$12,000.002,248,302View SEC Filing  
1/8/2016Value Fund L P BiotechnologyInsiderBuy1,001,327$1.22$1,221,618.94View SEC Filing  
1/4/2016Matthew PlunkettEVPSell10,000$1.21$12,100.00610,084View SEC Filing  
12/30/2015James A. BiancoCEOSell110,000$1.26$138,600.002,258,302View SEC Filing  
12/28/2015James A. BiancoCEOSell10,000$1.29$12,900.002,258,302View SEC Filing  
12/18/2015Jack W. SingerEVPSell15,000$1.18$17,700.001,306,850View SEC Filing  
12/4/2015Matthew PlunkettEVPSell10,000$1.00$10,000.00620,084View SEC Filing  
11/27/2015Jack W. SingerEVPSell15,000$1.21$18,150.001,321,850View SEC Filing  
11/27/2015James A BiancoCEOSell10,000$1.23$12,300.002,951,519View SEC Filing  
11/19/2015Louis A. BiancoEVPSell15,000$1.13$16,950.00906,347View SEC Filing  
10/30/2015James A BiancoCEOSell260,000$1.35$351,000.002,961,519View SEC Filing  
10/29/2015Louis A. BiancoEVPSell10,000$1.41$14,100.00921,347View SEC Filing  
10/23/2015Jack W. SingerEVPSell15,000$1.62$24,300.001,336,850View SEC Filing  
10/22/2015Louis A BiancoEVPSell10,000$1.58$15,800.00931,347View SEC Filing  
10/5/2015Matthew PlunkettEVPSell10,000$1.52$15,200.00640,084View SEC Filing  
9/30/2015Jack W. SingerEVPSell100,000$1.42$142,000.001,351,850View SEC Filing  
9/30/2015James A. BiancoCEOSell600,000$1.43$858,000.003,221,519View SEC Filing  
9/30/2015Richard L. LoveDirectorSell13,660$1.45$19,807.00530,449View SEC Filing  
9/29/2015Louis A. BiancoEVPSell170,000$1.41$239,700.00941,347View SEC Filing  
9/25/2015Jack W. SingerEVPSell15,000$1.64$24,600.001,451,850View SEC Filing  
9/24/2015Matthew PlunkettEVPSell75,869$1.57$119,114.33725,084View SEC Filing  
9/4/2015Matthew PlunkettEVPSell10,000$1.54$15,400.00649,214View SEC Filing  
8/28/2015Jack W. SingerEVPSell15,000$1.58$23,700.001,260,919View SEC Filing  
7/24/2015Jack W SingerEVPSell15,000$1.91$28,650.00View SEC Filing  
7/23/2015Louis A BiancoEVPSell10,000$1.91$19,100.00View SEC Filing  
7/6/2015Matthew PlunkettEVPSell10,000$1.95$19,500.00View SEC Filing  
6/26/2015Jack W SingerEVPSell15,000$2.07$31,050.00View SEC Filing  
6/25/2015Louis A BiancoEVPSell10,000$2.18$21,800.00View SEC Filing  
6/4/2015Matthew PlunkettEVPSell10,000$2.06$20,600.00View SEC Filing  
5/22/2015Jack W SingerEVPSell15,000$1.74$26,100.00View SEC Filing  
5/21/2015Louis A BiancoEVPSell10,000$1.80$18,000.00View SEC Filing  
5/4/2015Matthew PlunkettEVPSell10,000$1.86$18,600.00View SEC Filing  
4/24/2015Jack W SingerEVPSell15,000$1.96$29,400.00View SEC Filing  
4/23/2015Louis A BiancoEVPSell10,000$1.93$19,300.00View SEC Filing  
4/6/2015Matthew PlunkettEVPSell16,569$1.88$31,149.72View SEC Filing  
3/23/2015James A BiancoCEOSell175,199$1.95$341,638.05View SEC Filing  
3/23/2015Matthew PlunkettEVPSell59,130$1.96$115,894.80View SEC Filing  
3/20/2015Louis A BiancoEVPSell63,000$1.94$122,220.00View SEC Filing  
2/27/2015Jack W SingerEVPSell15,000$2.35$35,250.00View SEC Filing  
2/5/2015Louis A BiancoEVPSell10,000$2.22$22,200.00View SEC Filing  
2/4/2015Matthew PlunkettEVPSell12,000$2.22$26,640.00View SEC Filing  
1/8/2015Louis A BiancoEVPSell10,000$2.32$23,200.00View SEC Filing  
1/5/2015Matthew PlunkettEVPSell12,000$2.36$28,320.00View SEC Filing  
12/19/2014James A BiancoCEOSell40,000$2.44$97,600.00View SEC Filing  
12/4/2014Louis A BiancoEVPSell10,000$2.25$22,500.00View SEC Filing  
11/6/2014Louis A BiancoEVPSell10,000$2.37$23,700.00View SEC Filing  
10/6/2014Matthew PlunkettEVPSell12,000$2.39$28,680.00View SEC Filing  
9/23/2014Matthew PlunkettEVPSell103,635$2.56$265,305.60View SEC Filing  
9/22/2014James A BiancoCEOSell307,068$2.53$776,882.04View SEC Filing  
9/22/2014Matthew PlunkettEVPSell51,817$2.58$133,687.86View SEC Filing  
9/19/2014Louis A BiancoEVPSell145,000$2.59$375,550.00View SEC Filing  
9/4/2014Matthew PlunkettEVPSell27,301$2.48$67,706.48View SEC Filing  
8/15/2014James A BiancoCEOSell40,000$2.54$101,600.00View SEC Filing  
8/4/2014Matthew PlunkettEVPSell12,000$2.48$29,760.00View SEC Filing  
7/10/2014Louis A BiancoEVPSell10,000$2.73$27,300.00View SEC Filing  
7/7/2014Matthew PlunkettEVPSell12,000$2.89$34,680.00View SEC Filing  
6/27/2014James A BiancoCEOSell50,000$2.84$142,000.00View SEC Filing  
6/5/2014Louis A BiancoEVPSell10,000$2.97$29,700.00View SEC Filing  
5/1/2014Louis BiancoEVPSell10,000$2.91$29,100.00812,897View SEC Filing  
3/28/2014Vartan GregorianDirectorSell82,000$3.41$279,620.00468,937View SEC Filing  
3/25/2014Phillip Phd NudelmanDirectorSell100,000$3.56$356,000.00448,619View SEC Filing  
3/24/2014Jack SingerEVPSell60,000$3.47$208,200.001,035,234View SEC Filing  
3/21/2014James BiancoCEOSell395,000$3.83$1,512,850.002,402,794View SEC Filing  
3/21/2014Matthew PlunkettEVPSell170,000$3.73$634,100.00620,904View SEC Filing  
3/7/2014Fred TellingDirectorSell72,095$3.75$270,356.25401,170View SEC Filing  
9/23/2013James A BiancoCEOSell130,551$1.50$195,826.50View SEC Filing  
8/30/2013James A BiancoCEOSell25,925$1.08$27,999.00View SEC Filing  
8/9/2013James A BiancoCEOSell40,000$1.07$42,800.00View SEC Filing  
8/7/2013Mary Oneil MundingerDirectorSell125,000$1.06$132,500.00View SEC Filing  
8/6/2013Phillip M Phd NudelmanDirectorSell50,000$1.09$54,500.00View SEC Filing  
7/26/2013James A BiancoCEOSell25,688$1.09$27,999.92View SEC Filing  
6/28/2013James A BiancoCEOSell26,053$1.08$28,137.24View SEC Filing  
6/5/2013Jack W SingerEVPSell10,000$1.26$12,600.00View SEC Filing  
5/31/2013James A BiancoCEOSell28,000$1.22$34,160.00View SEC Filing  
5/31/2013Louis A BiancoEVPSell33,712$1.24$41,802.88View SEC Filing  
5/30/2013Fred TellingDirectorSell64,798$1.24$80,349.52View SEC Filing  
5/24/2013Richard L LoveDirectorSell23,000$1.21$27,830.00View SEC Filing  
5/10/2013James A BiancoCEOSell25,000$1.16$29,000.00View SEC Filing  
5/9/2013Louis A BiancoEVPSell50,000$1.15$57,500.00View SEC Filing  
3/11/2013Jack W SingerEVPSell13,000$1.28$16,640.00View SEC Filing  
8/10/2012James A BiancoCEOSell10,000$0.42$4,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CTI BioPharma (NASDAQ CTIC) News Headlines

Source:
DateHeadline
CTI BioPharma (CTIC) Given Average Recommendation of "Buy" by BrokeragesCTI BioPharma (CTIC) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 21 at 7:38 AM
Jefferies Group Research Analysts Cut Earnings Estimates for CTI BioPharma (CTIC)Jefferies Group Research Analysts Cut Earnings Estimates for CTI BioPharma (CTIC)
www.americanbankingnews.com - May 11 at 9:04 AM
$300,000.00 in Sales Expected for CTI BioPharma (CTIC) This Quarter$300,000.00 in Sales Expected for CTI BioPharma (CTIC) This Quarter
www.americanbankingnews.com - May 11 at 1:46 AM
CTI BioPharma Forecasted to Post FY2022 Earnings of $0.21 Per Share (CTIC)CTI BioPharma Forecasted to Post FY2022 Earnings of $0.21 Per Share (CTIC)
www.americanbankingnews.com - May 10 at 9:37 AM
 Analysts Expect CTI BioPharma (CTIC) to Post -$0.24 Earnings Per Share Analysts Expect CTI BioPharma (CTIC) to Post -$0.24 Earnings Per Share
www.americanbankingnews.com - May 9 at 9:10 PM
BrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in LondonBrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in London
www.prnewswire.com - May 9 at 1:14 AM
CTI BioPharma (CTIC) Stock Rating Upgraded by ValuEngineCTI BioPharma (CTIC) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 8 at 11:54 PM
FY2021 EPS Estimates for CTI BioPharma Raised by Analyst (CTIC)FY2021 EPS Estimates for CTI BioPharma Raised by Analyst (CTIC)
www.americanbankingnews.com - May 7 at 5:20 AM
CTI BIOPHARMA CORP.CTI BIOPHARMA CORP.
www.streetinsider.com - May 5 at 4:29 PM
BRIEF-Cti Biopharma Reports Q1 EPS Loss Per Share Of $0.08BRIEF-Cti Biopharma Reports Q1 EPS Loss Per Share Of $0.08
www.reuters.com - May 5 at 4:29 PM
CTI BioPharma beats by $0.02, beats on revenueCTI BioPharma beats by $0.02, beats on revenue
seekingalpha.com - May 4 at 9:20 AM
CTI BioPharmas (CTIC) CEO Adam Craig on Q1 2018 Results - Earnings Call TranscriptCTI BioPharma's (CTIC) CEO Adam Craig on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 9:20 AM
CTI BioPharma: 1Q Earnings SnapshotCTI BioPharma: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 9:20 AM
CTI BioPharma (CTIC) Releases Quarterly  Earnings Results, Misses Expectations By $0.01 EPSCTI BioPharma (CTIC) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 3 at 10:52 PM
CTI BioPharma Reports First Quarter 2018 Financial ResultsCTI BioPharma Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 4:27 PM
CTI BioPharma Corp (NASDAQ:CTIC) Is Trading At A 22% DiscountCTI BioPharma Corp (NASDAQ:CTIC) Is Trading At A 22% Discount
finance.yahoo.com - May 3 at 9:17 AM
CTI BioPharma (CTIC) Set to Announce Earnings on ThursdayCTI BioPharma (CTIC) Set to Announce Earnings on Thursday
www.americanbankingnews.com - April 27 at 10:14 AM
CTI BioPharma to Report First Quarter 2018 Financial Results on May 3, 2018CTI BioPharma to Report First Quarter 2018 Financial Results on May 3, 2018
finance.yahoo.com - April 26 at 4:30 PM
CTI BioPharma (CTIC) Receives Consensus Rating of "Buy" from AnalystsCTI BioPharma (CTIC) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 26 at 8:52 AM
CTI BioPharma (CTIC) Raised to Hold at Zacks Investment ResearchCTI BioPharma (CTIC) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 25 at 7:54 PM
Does CTI BioPharma Corp’s (NASDAQ:CTIC) Latest Financial Perfomance Look Strong?Does CTI BioPharma Corp’s (NASDAQ:CTIC) Latest Financial Perfomance Look Strong?
finance.yahoo.com - April 25 at 4:39 PM
$10.30 Million in Sales Expected for CTI BioPharma (CTIC) This Quarter$10.30 Million in Sales Expected for CTI BioPharma (CTIC) This Quarter
www.americanbankingnews.com - April 24 at 3:02 AM
Zacks: Analysts Expect CTI BioPharma (CTIC) Will Post Earnings of -$0.07 Per ShareZacks: Analysts Expect CTI BioPharma (CTIC) Will Post Earnings of -$0.07 Per Share
www.americanbankingnews.com - April 22 at 1:16 PM
What Should You Know About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trajectory?What Should You Know About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trajectory?
finance.yahoo.com - April 18 at 4:46 PM
CTI BioPharma (CTIC) Rating Lowered to Sell at Zacks Investment ResearchCTI BioPharma (CTIC) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 17 at 10:19 PM
Analyzing CTI BioPharma (CTIC) & Amarin (AMRN)Analyzing CTI BioPharma (CTIC) & Amarin (AMRN)
www.americanbankingnews.com - April 9 at 11:13 AM
Needham & Company Starts CTI BioPharma (CTIC) at BuyNeedham & Company Starts CTI BioPharma (CTIC) at Buy
www.streetinsider.com - April 7 at 9:57 AM
$10.30 Million in Sales Expected for CTI BioPharma Corp (CTIC) This Quarter$10.30 Million in Sales Expected for CTI BioPharma Corp (CTIC) This Quarter
www.americanbankingnews.com - April 7 at 2:48 AM
 Analysts Anticipate CTI BioPharma Corp (CTIC) to Post -$0.07 EPS Analysts Anticipate CTI BioPharma Corp (CTIC) to Post -$0.07 EPS
www.americanbankingnews.com - April 5 at 3:18 PM
CTI BioPharma Corp (CTIC) Receives Consensus Rating of "Buy" from BrokeragesCTI BioPharma Corp (CTIC) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 1 at 9:37 AM
Seeing Value In CTI BioPharma: Compelling Data, Recent M&A Validate Pacritinib In MyelofibrosisSeeing Value In CTI BioPharma: Compelling Data, Recent M&A Validate Pacritinib In Myelofibrosis
seekingalpha.com - March 29 at 4:29 PM
CTI BioPharma pays CEO $5.6 million in his first yearCTI BioPharma pays CEO $5.6 million in his first year
www.bizjournals.com - March 29 at 4:29 PM
CTI BioPharma (CTIC) Earns Buy Rating from Analysts at Needham & Company LLCCTI BioPharma (CTIC) Earns Buy Rating from Analysts at Needham & Company LLC
www.americanbankingnews.com - March 26 at 8:37 AM
CTI BioPharma Corp (CTIC) Expected to Post Quarterly Sales of $10.30 MillionCTI BioPharma Corp (CTIC) Expected to Post Quarterly Sales of $10.30 Million
www.americanbankingnews.com - March 21 at 8:49 AM
SA Interview: Biotechnology Investing With Juggernaut Capital - CTI ... - Seeking AlphaSA Interview: Biotechnology Investing With Juggernaut Capital - CTI ... - Seeking Alpha
seekingalpha.com - March 19 at 4:23 PM
SA Interview: Biotechnology Investing With Juggernaut Capital - Seeking AlphaSA Interview: Biotechnology Investing With Juggernaut Capital - Seeking Alpha
seekingalpha.com - March 19 at 4:23 PM
 Brokerages Expect CTI BioPharma Corp (CTIC) to Post -$0.07 EPS Brokerages Expect CTI BioPharma Corp (CTIC) to Post -$0.07 EPS
www.americanbankingnews.com - March 19 at 3:16 PM
Active-Investors: Wired News - CTI BioPharmas Pacritinib Phase-3 PERSIST-2 Clinical Trial Data Published in JAMA OncologyActive-Investors: Wired News - CTI BioPharma's Pacritinib Phase-3 PERSIST-2 Clinical Trial Data Published in JAMA Oncology
www.finanznachrichten.de - March 13 at 9:45 AM
CTI BioPharma Corp (CTIC) to Post Q1 2018 Earnings of ($0.07) Per Share, Jefferies Group ForecastsCTI BioPharma Corp (CTIC) to Post Q1 2018 Earnings of ($0.07) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - March 12 at 2:32 AM
CTI BioPharma (CTIC) Earns Outperform Rating from Analysts at JMP SecuritiesCTI BioPharma (CTIC) Earns Outperform Rating from Analysts at JMP Securities
www.americanbankingnews.com - March 11 at 3:19 PM
CTI BioPharma (CTIC) Reports Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMACTI BioPharma (CTIC) Reports Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA
www.streetinsider.com - March 9 at 5:31 PM
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA OncologyCTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
finance.yahoo.com - March 9 at 9:58 AM
CTI BioPharma to Present at Upcoming Investor ConferencesCTI BioPharma to Present at Upcoming Investor Conferences
finance.yahoo.com - March 9 at 9:58 AM
CTI BioPharma (CTIC) Rating Reiterated by CannCTI BioPharma (CTIC) Rating Reiterated by Cann
www.americanbankingnews.com - March 8 at 12:28 AM
CTI BioPharma (CTIC) Releases Quarterly  Earnings Results, Misses Expectations By $0.04 EPSCTI BioPharma (CTIC) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - March 7 at 9:14 PM
CTI BioPharma Corp (NASDAQ:CTIC): What Does It Mean For Your Portfolio?CTI BioPharma Corp (NASDAQ:CTIC): What Does It Mean For Your Portfolio?
finance.yahoo.com - March 7 at 5:17 PM
CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial ResultsCTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results
www.prnewswire.com - March 7 at 4:07 PM
CTI BioPharma Corp (CTIC) Receives Consensus Recommendation of "Buy" from AnalystsCTI BioPharma Corp (CTIC) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 7 at 2:08 PM
Stonepine Capital Management LLC Purchases 841,838 Shares of CTI BioPharma Corp (CTIC)Stonepine Capital Management LLC Purchases 841,838 Shares of CTI BioPharma Corp (CTIC)
www.americanbankingnews.com - March 6 at 10:02 AM
$1.00 Million in Sales Expected for CTI BioPharma Corp (CTIC) This Quarter$1.00 Million in Sales Expected for CTI BioPharma Corp (CTIC) This Quarter
www.americanbankingnews.com - March 4 at 7:38 AM

SEC Filings

CTI BioPharma (NASDAQ:CTIC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CTI BioPharma (NASDAQ:CTIC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CTI BioPharma (NASDAQ CTIC) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.